DI
BBIO icon

Disciplined Investments’s BridgeBio Pharma BBIO Stock Holding History

Disciplined Investments’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10
Closed -$172 – 248
2023
Q2 		$172 Buy
10
+5
+100% +$75 ﹤0.01% 1524
2023
Q1 		$83 Buy
5
+2
+67% +$23 ﹤0.01% 1596
2022
Q4 		$23 Sell
3
-2
-40% -$19 ﹤0.01% 1624
2022
Q3 		$0 Buy
5
+1
+25% +$10 ﹤0.01% 1234
2022
Q2 		$0 Buy
4
+1
+33% +$8 ﹤0.01% 1265
2022
Q1 		$0 Buy
+3
New +$31 ﹤0.01% 1339

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Disciplined Investments's BBIO Position: Q3 2023 in Review

Disciplined Investments sold out of BridgeBio Pharma (BBIO) in Q3 2023, closing a stake of 10 shares — an estimated $172 sold.

Disciplined Investments first reported a position in BBIO in Q1 2022 and held it in 6 quarters. The position peaked at $172 in Q2 2023. 221 funds tracked by Wall St. Rank hold BBIO as of Q3 2023.

  • Disciplined Investments reported no remaining BridgeBio Pharma position as of Q3 2023 after selling out during the quarter.
  • Disciplined Investments sold 10 BridgeBio Pharma shares in Q3 2023, an estimated $172.
  • Disciplined Investments first reported a position in BridgeBio Pharma in Q1 2022 and held it in 6 quarters.
  • Disciplined Investments's BridgeBio Pharma position peaked at $172 in Q2 2023.
  • 221 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2023.

Based on Disciplined Investments's 13F filing for Q3 2023, filed 14 Nov 2023.